For our first Snapshot for the BIO CEO event, we've spoken with NuPathe Inc. about their priorities, challenges, and what you can expect from their company.
What are the short-term and long-term priorities for your company?
We develop innovative neuroscience treatments for the millions of people who suffer from neurologic diseases and disorders, far too many of whom are underserved by current treatments. Our short-term focus is to gain FDA approval for and successfully launch our migraine patch product candidate, which has been clinically tested for the treatment of debilitating headache pain and migraine-related nausea. Looking ahead, we plan to develop and commercialize valuable neurologic treatments across a range of therapeutic areas.
How does your company go about differentiating yourselves from the competition?
If approved by FDA, our migraine patch will be a perfect foundation product for our company because it would address the need for a better non-oral treatment for migraine patients. We intend to use this foundation to help us advance our earlier stage pipeline product candidates for Parkinson’s disease, schizophrenia and bipolar disorder and to use our underlying technologies to build our current pipeline beyond current preclinical and clinical programs.
What is the most challenging part of raising money and seeking collaborations?
Clearly the challenges in accessing growth capital can negatively impact the pipeline of innovative therapies from both small and large pharmaceutical companies. We believe these challenges offer an opportunity to simplify our approach to deliver tailored therapeutic solutions to underserved patient populations. As an emerging company, this environment demands smart innovation – developing treatments and collaborations that not only improve on existing drugs or technologies but do so in a manner that truly meets a patient need.
Tell us something about your company that investors might not know.
Our earlier-stage pipeline includes two promising product candidates for global patient populations that utilize our LAD or long-acting delivery technology, a biodegradable implant that is injected subcutaneously to deliver the desired medication over a period of three to six months. NP201, is being developed for the continuous symptomatic treatment of Parkinson’s disease with the delivery of ropinirole, a leading FDA-approved dopamine agonist, and is designed to potentially provide up to two months of continuous delivery. NP202, being developed for schizophrenia and bipolar disorder, is designed to address patient noncompliance, a long-standing problem in the treatment of these conditions, by potentially providing three to six months of continuous delivery of an atypical antipsychotic.
Thanks to NuPathe for participating in the Company Snapshots, and don't forget to catch their presentation at the event! All presentation times will be posted on our 2012 Presenting Company list, and you can also find them in the One-on-One Partnering System.